Suppr超能文献

含腺苷的组蛋白甲基转移酶 DOT1L 抑制剂的合成及构效关系研究。

Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.

机构信息

Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA.

出版信息

J Med Chem. 2012 Sep 27;55(18):8066-74. doi: 10.1021/jm300917h. Epub 2012 Sep 6.

Abstract

Histone3-lysine79 (H3K79) methyltransferase DOT1L has been found to be a drug target for acute leukemia with MLL (mixed lineage leukemia) gene translocations. A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM. These compounds also show high selectivity (>4500-fold) over three other histone methyltransferases. Structure-activity relationships (SAR) of these compounds for their inhibitory activities against DOT1L are discussed. Potent DOT1L inhibitors exhibit selective activity against the proliferation of MLL-translocated leukemia cell lines MV4;11 and THP1 with EC(50) values of 4-11 μM. Isothermal titration calorimetry studies showed that two representative inhibitors bind with a high affinity to the DOT1L:nucleosome complex and only compete with the enzyme cofactor SAM (S-adenosyl-L-methionine) but not the substrate nucleosome.

摘要

组蛋白 3-赖氨酸 79(H3K79)甲基转移酶 DOT1L 已被发现是具有 MLL(混合谱系白血病)基因易位的急性白血病的药物靶点。共设计和合成了 55 种含腺苷的化合物,其中鉴定出几种具有低至 0.5 nM 的 K(i)值的有效 DOT1L 抑制剂。这些化合物对其他三种组蛋白甲基转移酶也具有高选择性(>4500 倍)。讨论了这些化合物对 DOT1L 抑制活性的结构-活性关系(SAR)。有效的 DOT1L 抑制剂对 MLL 易位白血病细胞系 MV4;11 和 THP1 的增殖表现出选择性活性,EC(50)值为 4-11 μM。等温滴定量热法研究表明,两种代表性抑制剂与 DOT1L:核小体复合物具有高亲和力,仅与酶辅因子 SAM(S-腺苷甲硫氨酸)竞争,而不与底物核小体竞争。

相似文献

2
A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
J Med Chem. 2013 Nov 27;56(22):8972-83. doi: 10.1021/jm4007752. Epub 2013 Aug 14.
3
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
J Am Chem Soc. 2011 Oct 26;133(42):16746-9. doi: 10.1021/ja206312b. Epub 2011 Oct 4.
4
Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Bioorg Chem. 2018 Oct;80:649-654. doi: 10.1016/j.bioorg.2018.07.022. Epub 2018 Jul 21.
6
Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Bioorg Med Chem. 2018 May 1;26(8):1751-1758. doi: 10.1016/j.bmc.2018.02.020. Epub 2018 Feb 24.
7
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Eur J Med Chem. 2020 Mar 1;189:112023. doi: 10.1016/j.ejmech.2019.112023. Epub 2020 Jan 2.
8
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Blood. 2013 Mar 28;121(13):2533-41. doi: 10.1182/blood-2012-11-465120. Epub 2013 Jan 29.
9
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Chem Biol Drug Des. 2012 Dec;80(6):971-80. doi: 10.1111/cbdd.12050. Epub 2012 Oct 9.
10
Structure-guided DOT1L probe optimization by label-free ligand displacement.
ACS Chem Biol. 2015 Mar 20;10(3):667-74. doi: 10.1021/cb500796d. Epub 2015 Jan 15.

引用本文的文献

2
3-(Adenosylthio)benzoic Acid Derivatives as SARS-CoV-2 Nsp14 Methyltransferase Inhibitors.
Molecules. 2023 Jan 12;28(2):768. doi: 10.3390/molecules28020768.
3
Lysine methyltransferase inhibitors: where we are now.
RSC Chem Biol. 2021 Dec 13;3(4):359-406. doi: 10.1039/d1cb00196e. eCollection 2022 Apr 6.
5
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
J Hematol Oncol. 2022 Mar 24;15(1):35. doi: 10.1186/s13045-022-01251-1.
6
Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Theranostics. 2021 Jul 13;11(17):8172-8184. doi: 10.7150/thno.56737. eCollection 2021.
8
Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis.
Cancers (Basel). 2021 Feb 5;13(4):642. doi: 10.3390/cancers13040642.
10
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Eur J Med Chem. 2020 Mar 1;189:112023. doi: 10.1016/j.ejmech.2019.112023. Epub 2020 Jan 2.

本文引用的文献

1
Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase.
ACS Med Chem Lett. 2012 Jun 14;3(6):496-500. doi: 10.1021/ml300071w. Epub 2012 May 7.
2
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
J Am Chem Soc. 2011 Oct 26;133(42):16746-9. doi: 10.1021/ja206312b. Epub 2011 Oct 4.
3
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
J Med Chem. 2011 Sep 8;54(17):6139-50. doi: 10.1021/jm200903z. Epub 2011 Aug 5.
4
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.
Nat Chem Biol. 2011 Jul 10;7(8):566-74. doi: 10.1038/nchembio.599.
5
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Cancer Cell. 2011 Jul 12;20(1):53-65. doi: 10.1016/j.ccr.2011.06.009.
6
Chemogenetic analysis of human protein methyltransferases.
Chem Biol Drug Des. 2011 Aug;78(2):199-210. doi: 10.1111/j.1747-0285.2011.01135.x. Epub 2011 Jun 16.
7
Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes.
ACS Med Chem Lett. 2011 Feb 10;2(2):165-170. doi: 10.1021/ml100243r.
10
Protein methyltransferases as a target class for drug discovery.
Nat Rev Drug Discov. 2009 Sep;8(9):724-32. doi: 10.1038/nrd2974.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验